Chimeric antigen receptor signaling domain

The development of a chimeric antigen receptor (CAR) with specific domains enhances the ability of T cells to target and kill cancer cells, addressing the challenge of immune evasion by cancer cells and improving cancer treatment efficacy.

JP2026086565APending Publication Date: 2026-05-26KITE PHARMA INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
KITE PHARMA INC
Filing Date
2026-02-05
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Current T-cell therapies for cancer treatment face challenges in effectively targeting and killing cancer cells due to mechanisms employed by cancer cells to evade immune cells, necessitating improved methods for generating antigen receptor-modified T cells that can specifically target and kill cancer cells in both self-generated and allogeneic environments.

Method used

Development of a chimeric antigen receptor (CAR) comprising an antigen-binding domain, transmembrane domain, costimulatory domain, and signaling domain, including CD3ε, CD3γ, CD3δ, or DAP-12 signaling domains, with specific amino acid sequences for enhanced targeting and killing of cancer cells, particularly those expressing CD19 antigens.

Benefits of technology

The CAR-modified T cells demonstrate improved efficacy in targeting and killing cancer cells, including various types of leukemia and lymphoma, by inducing an immune response and activating T cells to enhance cancer cell destruction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026086565000089
    Figure 2026086565000089
  • Figure 2026086565000090
    Figure 2026086565000090
  • Figure 2026086565000091
    Figure 2026086565000091
Patent Text Reader

Abstract

This invention provides an improved method for generating antigen receptor-modified T cells that specifically target and kill cancer cells in a self-generated or allogeneic environment. [Solution] A chimeric antigen receptor (CAR) is disclosed, comprising an antigen-binding domain, a transmembrane domain, a costimulatory domain, and a signaling domain comprising one of the following: a CD3ε signaling domain, a CD3γ signaling domain, a CD3δ signaling domain, or a DAP12 signaling domain. A nucleic acid encoding a CAR and a recombinant vector comprising such a nucleic acid are disclosed. A host cell comprising such a nucleic acid and recombinant vector, and a pharmaceutical composition comprising such a host cell are disclosed. Methods for treating a disease in a patient requiring treatment of the disease, or for inducing an immune response in a subject, or for immunizing a subject against cancer are disclosed.
Need to check novelty before this filing date? Find Prior Art